AMR Industry Alliance

The AMR Industry Alliance brings together over 100 biotech, diagnostics, generics and research-based pharmaceutical companies and associations, to drive and measure the life-sciences’ industry progress to curb antimicrobial resistance.

The AMR Industry Alliance ensures that signatories collectively deliver on the specific commitments, originally made in the Declaration (January 2016) and the Roadmap (September 2016) and updated in 2019. The Alliance measures and drives industry’s progress in the fight against antimicrobial resistance.

Today, an estimated 700,000 people die each year because of the growing number of potentially deadly infectious pathogens, including those that cause tuberculosis, HIV, malaria and staph infections, that have developed resistance to treatment regimens. In response to this public health threat that has the potential to turn the clock back on modern medicine and the social and economic consequences associated with it, the United Nations called in 2016 for concerted action from governments and various sectors, to address the implications of antimicrobial resistance. The AMR Industry Alliance is the life sciences industry’s response to call for action.

In an unprecedented effort, over 100 companies and associations signed the Industry Declaration on AMR at the World Economic Forum in Davos in 2016, followed by the adoption of a Roadmap, outlining a common set of principles for global action that focuses on investing in R&D to meet public health needs, reducing the development of antimicrobial resistance, improving access to antibiotics, vaccines and diagnostics, and reducing the environmental impact of manufacturing.

The AMR Industry Alliance launched its first Progress Report on 18 January 2018 (see Press Release here). This report shows the commitment of the life sciences industry to tackle the public health threat of antimicrobial resistance (AMR).

The data and case studies collected in the Alliance report provide unique insights into the practical steps Alliance’s members are taking to respond to AMR in the areas of research and science, access, appropriate use, and the environment.

In 2019, the Alliance revised its commitments to better reflect the ongoing fight against AMR and progress already made by its members, particularly on manufacturing and the environment.

Subsequently in 2020, on 16 January, the Alliance released its second Progress Report (see Press Release here), with the foreword by professor Dame Sally Davies.

These reports provide a unique snapshot of the life sciences industry’s collective efforts and leadership in delivering on their global commitments and action to tackle this rise of antimicrobial resistance in the areas of research and science, access, appropriate use, and environmental manufacturing.

Alliance records US1.6B annual investment (in 2018) in antimicrobial resistance (AMR)-relevant R&D. Concerning shortfall is in late stage R&D investment where the amount is likely insufficient to meet global health needs and risks undermining early pipeline investments in R&D and new diagnostics. Investments in AMR related products could increase if governments take action to improve antibiotic reimbursement and implement new incentives.

Alliance takes leadership role in responsible manufacturing of antibiotics, establishing an industry standard for reducing potential environmental risks from antibiotics production two years ahead of schedule.

Next steps include sharing R&D information to support innovation and surveillance data to track resistance, deploying diagnostics and vaccines in support of improved appropriate use and working with health authorities to tackle antibiotic shortages.


The AMR Industry Alliance is launched


Members across the life-sciences industry


Second Progress Report released

Related Resources